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ABSTRACT
Cardiac magnetic resonance (CMR) imaging provides accurate anatomic information 
and advanced soft contrast, making it the reference standard for assessing cardiac 
volumes and systolic function. In this review, we summarize the recent advances in CMR 
sequences. New technical development has widened the use of CMR imaging beyond the 
simple characterization of myocardial scars and assessment of contractility. These novel 
CMR sequences offer comprehensive assessments of coronary plaque characterization, 
myocardial fiber orientation, and even metabolic activity, and they can be readily applied 
in clinical settings. CMR imaging is able to provide new insights into understanding the 
pathophysiologic process of underlying cardiac disease, and it can help physicians choose the 
best treatment strategies. Although several limitations, including the high cost and time-
consuming process, have limited the widespread clinical use of CMR imaging so far, recent 
advances in software and hardware technologies have made the future more promising.
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INTRODUCTION
Cardiac magnetic resonance (CMR) imaging provides accurate anatomic information along 
with advanced soft contrast, which enables superior discrimination of lesions compared to 
other imaging modalities. Currently, CMR imaging is considered the reference standard for 
quantification of the cardiac chamber size and systolic function of the heart.1) Further, tissue 
characterization techniques including late gadolinium enhancement (LGE), T1 mapping, T2 
mapping, and T2-star mapping provide insight into the pathophysiological changes of the 
myocardium.2)3)
The drawbacks for the clinical application of CMR imaging have been the long acquisition 
time, relatively low spatial resolution, and high costs. However, new technical advances 
in hardware and software components accelerated the image acquisition time, and the 
introduction of 3T magnetic resonance imaging (MRI) has further improved the spatial 
resolution and diagnostic accuracy of CMR imaging in the assessment of the myocardium 
Korean Circ J. 2019 Feb;49(2):146-159
https://doi.org/10.4070/kcj.2018.0246
pISSN 1738-5520·eISSN 1738-5555
Review Article
Received: Jul 25, 2018
Revised: Sep 25, 2018
Accepted: Oct 23, 2018
Correspondence to
Hyuk-Jae Chang, MD, PhD
Division of Cardiology, Severance 
Cardiovascular Hospital, Yonsei-Cedars-Sinai 
Integrative Cardiovascular Imaging Research 
Center, Yonsei University College of Medicine, 
Yonsei University Health System, 50-1,  
Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
E-mail: hjchang@yuhs.ac
Copyright © 2019. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Yibin Xie 
https://orcid.org/0000-0002-0333-567X
Hyuk-Jae Chang 
https://orcid.org/0000-0002-6139-7545
Funding
This study was supported by Leading Foreign 
Research Institute Recruitment Program 
through the National Research Foundation of 
Korea funded by the Ministry of Science, ICT & 
Future Planning (grant No. 2012027176).
Sang-Eun Lee, MD, PhD1,2,3, Christopher Nguyen, PhD3,4,5, Yibin Xie , PhD3,  
Zixin Deng, PhD3, Zhengwei Zhou, PhD3, Debiao Li, PhD3, and  
Hyuk-Jae Chang , MD, PhD1,2
1 Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei 
University Health System, Seoul, Korea
2Integrative Cardiovascular Imaging Center, Yonsei University Health System, Seoul, Korea
3Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
4Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, USA
5Harvard Medical School, Boston, MA, USA
Recent Advances in Cardiac Magnetic 
Resonance Imaging
Conflict of Interest
The authors have no financial conflicts of 
interest.
Author Contributions
Conceptualization: Chang HJ, Lee SE; 
Supervision: Chang HJ, Li D; Writing - original 
draft: Lee SE; Writing - review & editing: Chang 
HJ, Lee SE, Nguyen C, Xie Y, Deng Z, Zhou Z, 
Li D.
and coronary arteries.1)4)5) Consequently, CMR imaging has become one of the routine clinical 
imaging investigations used for assessing patients with various cardiac diseases.
In this review, we summarize the recent advances in CMR imaging techniques that can readily 
be applied in clinical practice.
IMAGING AND CHARACTERIZATION OF THE 
MYOCARDIUM
T1 and T2 mapping
CMR imaging is optimized for characterization of the myocardium through its excellent 
soft-tissue contrast and various different imaging parameters, and it can provide insight into 
disease etiologies and the extent and stage of the diseases.6)7) Recently, more sophisticated 
CMR imaging techniques that can provide myocardial tissue characterization beyond the 
presence of myocardial fibrosis have been introduced.8) Native T1 mapping techniques and 
extracellular volume (ECV) fraction quantification can go beyond LGE imaging and identify 
more diffuse interstitial fibrosis.9)10)
Native T1 value is a composite signal of myocytes and ECV, and is influenced by the filed 
strength, with higher values at 3T than at 1.5T.11) The native T1 mapping does not require 
gadolinium-based contrast agents and hence is feasible in patients with renal impairment.12) 
The native (non-contrast) T1 mapping can detect pathophysiological process including diffuse 
interstitial fibrosis, myocardial edema, protein deposition, and other T1-altering substances 
including iron and lipid.13) In conditions that causes myocardial edema (e.g. acute myocardial 
infarction) or an increase of interstitial space (e.g. interstitial fibrosis caused by infarction or 
cardiomyopathies), the native T1 value increases. In case of lipid (e.g. Anderson-Fabry disease) 
or iron overload, the native T1 value decreases. Therefore, changes in myocardial T1 reflects 
various cardiac and systemic conditions.12)
ECV expansion is a main feature of heart failure, and ECV is a marker of myocardial 
remodeling.14) For the calculation of the ECV fraction, contrast-enhanced T1 mapping is 
used.12) Gadolinium-based contrast agents are distributed throughout the interstitial space 
and shorten T1 relaxation times proportional to the local concentration of gadolinium. 
Therefore, myocardial segments with fibrosis and scar exhibit shorter T1 relaxation 
times after the contrast administration. Calculation of the ECV requires measurement of 
myocardial and blood T1 before and after the contrast enhancement. In healthy individuals, 
normal ECV values of 25.3±3.5% in 1.5T have been reported.15) An increase in ECV is mostly 
caused by excessive collagen deposition and is thus represents myocardial fibrosis, and ECV 
reduces in the presence of thrombus or fat/lipomatous metaplasia.
Both native T1 mapping and ECV can help the differential diagnosis of patients with chest 
pain, and also can provide information for the distinction of acute from chronic conditions.9) 
Native T1 values of chronic myocardial infarction is lower and less extensive compared with 
acute stage, and the ECV of chronic myocardial infarction is significantly elevated than 
normal but lower than acute conditions. In recent studies, native T1 was also an important 
predictor of clinical outcomes in patients with CAD.10)14) Native T1 and ECV can also be 
applied in the assessment of non-ischemic cardiomyopathies. Native T1 was mildly elevated 
in patients with hypertrophic cardiomyopathy and was highest in segments that subsequently 
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demonstrated LGE.16) Native T1 was able to accurately discriminate hypertrophic 
cardiomyopathy from hypertensive heart disease,17) and was better in discriminating 
cardiomyopathies from the normal hearts.18)
The T2 mapping can accurately and reliably detect areas of myocardial edema, a hallmark of 
acute inflammation,8)19) and has been shown to be useful in acute myocardial infarction,20) 
myocarditis,21) stress cardiomyopathy,21) and cardiac allograft rejection.22) For this, 
conventional T2-weighted short-τ inversion recovery (T2-STIR) has been most commonly 
used and helpful in differentiating acute infarction from chronic infarction.23) However, 
as it depends on regional differences in myocardial signal intensity, its interpretation is 
qualitative and subjective.24)25) T2 mapping is more reproducible than T2-STIR,26) and it can 
overcome this limitation of classic T2-STIR.27)28) T2 values can be directly quantified in vivo, as 
a surrogate for myocardial water content.29) Normal T2 values acquired with steady-state free 
precession MRI have been reported to be 52.18±3.4 ms at 1.5T and 45.1 ms at 3T.30)31) Studies 
have shown that T2 values are increased in the state of advanced heart failure, representing 
decompensation and decreases after treatment.28) In a recent study, T2 mapping was superior 
compared with T1 mapping and ECV for the assessment of the myocarditis in patients with 
recent-onset heart failure with reduced ejection fraction.27)
Recently, a novel MRI sequence named CMR multitasking that enables simultaneous T1 
mapping, T1/T2 mapping, and time-resolved T1 mapping and hence markedly reduces 
the total acquisition time has been introduced.32) CMR multitasking uses a continuous 
acquisition approach, which conceptualizes the physiological motions and other dynamic 
processes as multiple time dimensions, making efficient quantitative CMR imaging possible 
without the use of electrocardiogram gating and breath holds.
Late gadolinium enhancement
The LGE technique is one of the most established methods in characterization of the 
myocardium using CMR imaging so far.2)7) LGE is a T1-weighted technique that can detect 
and quantify areas of myocardial injury and cardiac infiltration in various cardiac diseases, 
and it has become the gold standard method for detecting myocardial scars. LGE uses the 
pattern and velocity of distribution and accumulation of the gadolinium-chelate contrast 
agent within the extracellular compartment of the myocardium.
Because the LGE pattern follows the pathophysiological process of the underlying disease, it 
helps identify the etiology of heart failure. In ischemic heart disease, the injury starts in the 
subendocardium and progresses into the transmural myocardium as ischemia continues.33) 
Thus, the LGE pattern in patients with CAD starts as subendocardial and extends 
transmurally, whereas that in patients with dilated cardiomyopathy demonstrates a linear 
mid-wall pattern in the interventricular septum.33)34)
Importantly, the presence and extent of LGE are significant prognostic indicators associated 
with an increased risk of future cardiac events, regardless of the underlying etiology or 
pattern of fibrosis.35-37) Further, LGE can assess viability of the myocardium in ischemic and 
non-ischemic cardiac disease; thereby, it has the potential to guide the clinical decision.37-40) 
The main limitation of LGE is that it is a marker of irreversible replacement fibrosis, the final 
pathophysiologic process of all cardiac diseases, and therefore is limited in assessing the 
early changes of cardiac diseases.41)42) Further, LGE is mostly useful in cardiac diseases which 
results in regional differences within the myocardium.37)
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Assessment of myocardial fiber orientation
CMR imaging can characterize the property of the myocardium and directly visualize the 
myocardial fiber architecture using diffusion tensor imaging (DTI).43)44) Previous preclinical 
studies have demonstrated the ability of DTI to evaluate therapeutic responses of the 
myocardial microstructure, including stem cell or surgical treatment, in animal and human 
models.45-49) Recently, technical advances have made the in vivo acquisition of DTI using 
clinical MR scanners possible in large animals and humans.50-52) The DTI technique has been 
evaluated most frequently in hypertrophic cardiomyopathy and myocardial infarction.45)53) 
Novel DTI was also feasible using a 3T clinical scanner.54)
The clinical application of DTI has been limited because the ability of DTI to delineate the 
microstructure of the myocardium has been histologically validated only using destructive 2D 
methods that perturb the original myocardial fiber orientation.55)56) The reliability of DTI was 
recently validated in normal and ischemic heart failure mice models, and the myocardial fiber 
orientation calculated by DTI was directly compared with histology using a non-destructive 3D 
method with the tissue-clearing technique.57) The correlations were significant in the normal 
and diseased models, showing the capability and accuracy of DTI for mapping the myocardial 
microstructure.58) Based on these observations, the clinical application of DTI using the 
clinical MRI system for characterizing the myocardial fiber architecture seems possible, and it 
can provide additional information to conventional viability characterizations (Figure 1).
Assessment of metabolic activity of the myocardium
To maintain its continuous contraction, the heart has a high rate of adenosine triphosphate 
(ATP) production and utilization.59) Previous studies have shown that cardiac dysfunction 
is associated with decreased myocardial ATP.60)61) Therefore, characterization of cardiac 
metabolism can be potentially useful in assessing disease progression and understanding the 
pathophysiology,59) and the direct measurement of metabolites involved in ATP synthesis can 
be used to assess myocardial ischemia, oxygenation, remodeling, and viability.62)
The chemical exchange saturation transfer (CEST) technique has been developed to quantify 
metabolites and macromolecules.63-65) In a recent study, CEST was able to map the creatine 
distribution within the myocardium to evaluate the metabolic activity in an animal model,66) 
and an optimized in vivo cardiac CEST sequence that maps free creatine in myocardial tissue, 
with a markedly reduced scan time by 10-fold and improved motion registration and signal 
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Figure 1. Representative image of diffusion tensor imaging (A) short-axis view of helix angle map and (B) tractography of the heart of a healthy mice, (C) diffusion 
image (left) and (D) corresponding helix angle map (right) of a patient with hypertrophic cardiomyopathy.
calculation, has been developed.67) The feasibility of the sequence has been tested against 
LGE imaging as a reference in a porcine myocardial infarction model, and the sequence has 
been applied in a patient with chronic myocardial infarction. The creatine CEST signal was 
significantly reduced in the infarct region compared to remote myocardium in animal and 
human models, and it was well correlated with LGE (Figure 2).
ASSESSMENT OF MYOCARDIAL PERFORMANCE WITH 
FEATURE TRACKING
Quantification of the myocardial contractility using myocardial strain has been one of the 
major interests in cardiac imaging and mainly driven by speckle-tracking echocardiography, 
but CMR can also be used for the assessment of myocardial strain. Previous myocardial 
tagging-based CMR strain measurements were proven to be accurate for measuring regional 
myocardial strain, but required the acquisition of additional images and significant post-
processing and hence limited its use in routine clinical practice.68) Recently, CMR feature 
tracking (FT) technique has enabled simultaneous assessment of both the left ventricular 
ejection fraction and strain using standard clinical steady-state free precession cine 
images.69)70) In a meta-analysis of the normal reference ranges reported for global strain 
metrics measured by CMR-FT, a significant heterogeneity in strain measurements between 
studies were found which was not explained by either technical or physiological factors.69) 
To reduce this variability between vendors and to facilitate the development of vendor-
independent normal references for the wider application of MR based strain measurements, 
the CMR-FT community is making a multivendor effort to standardize methodology for 
acquisition, post-processing, and reporting of CMR-FT strain results.68)
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Figure 2. Representative images of chemical exchange saturation transfer in (A) a normal volunteer and (B) a 
patient with a history of acute myocardial infarction at right coronary artery. Arrow indicates the hypointensive 
segment corresponding to the inferior segment affected by acute myocardial infarction. 
AMI = acute myocardial infarction; RCA = right coronary artery.
CORONARY ARTERY PLAQUE IMAGING
Coronary magnetic resonance angiography
The modality of choice for assessing the coronary arteries remains invasive coronary 
angiography, which mainly focuses on delineating the vessel walls and luminal stenosis. As 
the needs for noninvasive imaging modalities that can evaluate coronary artery disease (CAD) 
emerge, attempts have been made to apply computed tomography (CT) and CMR imaging 
to the assessment of CAD. However, the application of CMR imaging in coronary artery 
imaging has been challenging because of the small size of coronary vessels and their complex 
motion; therefore, CMR imaging has lagged compared to CT angiography. Nevertheless, 
CMR imaging has several merits over CT, including superior soft-tissue contrast that 
possibly allows superior characterization of high-risk plaques and the lack of radiation 
exposure, which makes CMR imaging an excellent imaging modality for longitudinal studies. 
Further, as there is no calcium blooming effect with CMR imaging, it is possible to perform 
luminal assessment in patients with severe calcification. These advantages coupled with 
the development of fully digital systems, multichannel receiver coils, parallel imaging, and 
higher field strengths have improved the image quality of CMR imaging and made coronary 
magnetic resonance angiography (MRA) an attractive imaging modality for assessing CAD.7)
Rapid sequences are essential in coronary MRA. For contrast-enhanced MRA, the spoiled 
gradient echo-like fast low-angle shot (e.g., TurboFLASH) is most commonly used.71) MRA 
can be also acquired without contrast using balanced steady-state free precession sequences, 
but gradient echo imaging with contrast is preferred in 3T or 7T MRI. The most commonly 
used contrast agent in coronary MRA is a chelated gadolinium-based agent. Contrast 
agents enhance the coronary lumen by shortening the T1 relaxation times of the blood 
pool. However, as gadolinium contrast is associated with nephrogenic systemic fibrosis, 
non-contrast MRA is gaining an important clinical role.72) The accuracy of coronary MRA 
in diagnosing luminal stenosis and quantitatively measuring the plaque burden has been 
validated in many previous studies.73-77) In meta-analyses, coronary MRA demonstrated an 
overall diagnostic accuracy of 72–79%, with an overall sensitivity of 87–89% and specificity of 
70–72% when compared to invasive coronary angiography.74)76)
Quantitative assessment of coronary vessel wall thickness
Coronary MRA also enables the quantitative measurement of plaque thickness and plaque 
burden. Current technological development in coronary MRA has mainly focused on 
shortening the scan time, improving motion correction, and reducing the flow dependency. 
The conventional 2-dimensional (2D) black-blood vessel wall imaging sequence has been 
improved, and flow-independent black-blood methods are available along with 3-dimensional 
(3D) black-blood vessel wall MRA.78-80) Currently, the standard method used in coronary 
MRA is 2D measurements of plaque wall thickness.81) The feasibility of coronary MRA in the 
quantitative assessment of coronary arterial wall thickness has been validated against that of 
intravascular ultrasonography,82)83) and the increased plaque thickness detected by coronary 
MRA in asymptomatic patients was associated with subclinical coronary atherosclerosis.84)
Intraplaque hemorrhage by magnetic resonance imaging
Both histological and imaging studies have identified so-called “high-risk plaque 
features,” including positive remodeling, a thin fibrous cap, intraplaque hemorrhage, 
microcalcification, and a large necrotic core.85-87) CMR imaging can also be used to identify 
these plaque characteristics.
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Intraplaque hemorrhage has a high signal and very short T1 relaxation time because of 
methemoglobin, a main component of an acute thrombus. Therefore, detecting a freshly 
formed thrombus due to coronary plaque rupture or erosion using black-blood T1-weighted 
MRI as the method of choice is possible. In a prospective single-center study, high-intensity 
plaque, defined as plaque with a plaque-to-myocardial signal intensity ratio (PMR) >1.4, was 
associated with an increased risk of subsequent adverse coronary events in patients with 
stable CAD.88) The increased PMR was also an independent predictor for adverse clinical 
outcomes at follow-up. The high-intensity signal of these plaques significantly reduced after 
intensive statin treatment,89) demonstrating the feasibility of evaluating the therapeutic 
response using coronary T1-weighted MRI.
One of the main limitations of these coronary T1-weighted MRI sequences based on 
conventional Cartesian acquisition and navigator gating is the intolerably long acquisition 
time. Because prior coronary T1-weighted MRI techniques heavily attenuate the signals 
from surrounding structures, the anatomic reference (coronary MRA) needs to be acquired 
separately and co-registered with T1-weighted images afterward in order to localize the high-
intensity signal of the coronary vasculature. Furthermore, the coverage has been limited to 
proximal segments, as spatial resolution was often anisotropic.88)
In this regard, we developed a highly accelerated magnetic resonance (MR) technique named 
coronary atherosclerosis T1-weighted characterization with integrated anatomical reference 
(CATCH) using a motion-compensated interleaved acquisition scheme that provides 
coronary T1-weighted images and integrated anatomical reference in one acquisition time, 
thereby shortening the total scan time to less than 25 minutes.90) This technique has been 
validated against optical coherence tomography, and coronary high-intensity plaques 
detected by CATCH were associated with lipid profiles and high-risk plaque characteristics 
detected by invasive coronary imaging (Figure 3).90)
NONINVASIVE MEASUREMENT OF THE PRESSURE 
GRADIENT
Fractional flow reserve (FFR) is defined as the ratio of the blood pressure distal to a site of 
stenosis (Pd) and the aortic pressure (Pa) during maximal hyperemia, and it represents the 
functional significance of coronary stenosis.91) Because the measurement of FFR requires 
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Anatomical reference Dark-blood T1-weighted Fusion
Figure 3. Representative image of pre-contrast coronary atherosclerosis T1-weighted characterization with 
integrated anatomical reference in a patient with a coronary hyperintensive plaque in the mid left anterior 
descending artery.
drug-induced hyperemia, instantaneous wave-free ratio (iFR), a drug-free method, which 
measures Pa and Pd during the middle to end diastolic phase, has been introduced.92) Previous 
studies have shown that FFR ≤0.80 and iFR ≤0.89 accurately identify significant stenoses that 
cause myocardial ischemia and require revascularization better than diameter stenoses.93)94)
Using the Navier-Stokes analysis, an FFR-like index using phase-contrast MRI called MR-iFR 
has been developed.95) In a preliminary study, the feasibility of the noninvasive blood pressure 
gradient and velocity measurement using phase-contrast MRI was demonstrated in phantoms 
and patients undergoing invasive FFR.95) MR-iFR showed good overall reproducibility of 
coronary flow velocity and excellent correlation with invasive measurements.
CURRENT LIMITATIONS OF CARDIAC MAGNETIC 
RESONANCE
Currently, CMR is not as widely used as like cardiac CT, mainly because of the long 
acquisition time and limitations in spatial and temporal resolution. To overcome these 
limitations, new techniques including compressed sensing and parallel imaging are being 
applied in various sequences.96) One of the major obstacles for the clinical application of 
CMR is also the lack of standardized protocol and the variation in CMR values related to 
equipment and sequences. Although efforts have been made including the publication 
of guidelines for the standardized protocol, image interpretation and post processing,2)3) 
the interchangeability between different vendors and magnet strengths are limited. The 
reference ranges for “normal” values for each CMR sequence are needed to be established 
as the difference between manufacturers, magnetic field strengths, and sequences varies 
widely. Further, the full clinical utility of various CMR values are yet unknown because only 
limited cardiac diseases have been studied for each sequence in separate conditions. Multi-
center, multivendor clinical trials are needed to fully establish the clinical utility of CMR in 
various cardiac diseases.
SUMMARY
CMR imaging offers comprehensive images of the heart in patients with various cardiac 
diseases. The prognostic value of CMR imaging is well established, and emerging novel 
technologies demonstrate the potential of CMR imaging to even change the clinical decision-
making process. Along with the rapid technological development, CMR imaging is able 
to provide new insights into understanding the pathophysiologic process of underlying 
cardiac disease, and it can help physicians choose the best treatment strategies. Although 
several limitations, including the high cost and time-consuming process, have limited the 
widespread clinical use of CMR imaging so far, recent advances in software and hardware 
technologies have made the future more promising.
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